We are live on !
Find out more
BGI
B Group Inc Portfolio holdings
AUM
$213M
Turnover
22.73%
1-Year Est. Return
96.05%
This Fund
S&P 500
This Quarter Est. Return
+22.25%
1 Year Est. Return
+96.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$213M
AUM Growth
+$78.1M
(+58%)
Cap. Flow
+$17.1M
Cap. Flow % of AUM
Cap. Flow %
8.04%
Top 10 Holdings %
Top 10 Hldgs %
79.47%
Holding
22
New
2
Increased
5
Reduced
1
Closed
3
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
1
year
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Faeth Therapeutics
FTH
|
+$14.1M |
| 2 |
NRX Pharmaceuticals
NRXP
|
+$3.61M |
| 3 |
Aura Biosciences
AURA
|
+$1.19M |
| 4 |
Structure Therapeutics
GPCR
|
+$553K |
| 5 |
ADMA Biologics
ADMA
|
+$501K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Spyre Therapeutics
SYRE
|
+$2.19M |
| 2 |
Apogee Therapeutics
APGE
|
+$631K |
| 3 |
Soleno Therapeutics
SLNO
|
+$251K |
| 4 |
Replimune Group
REPL
|
+$199K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.71% |
| 2 | Miscellaneous | 17.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$485B
| $36.8M | 17.29% |
+50,000
| New | +$34.4M |
2026 Q2
0 quarters
|
|
|
2
ADMA Biologics
ADMA
$2.48B
| $27.3M | 12.82% |
3,262,542
+55,000
| +2% | +$501K |
2024 Q4
6 quarters
|
|
3
Palisade Bio
PALI
$234M
| $23.9M | 11.2% |
11,414,285
| – | – |
2025 Q4
2 quarters
|
|
|
4
NRX Pharmaceuticals
NRXP
$114M
| $16.7M | 7.86% |
4,091,767
+1,091,767
| +36% | +$3.61M |
2026 Q1
1 quarter
|
|
|
5
Faeth Therapeutics
FTH
$502M
| $15.3M | 7.16% |
+610,169
| New | +$14.1M |
2026 Q2
0 quarters
|
|
6
Taysha Gene Therapies
TSHA
$1.28B
| $12.3M | 5.76% |
1,800,556
| – | – |
2024 Q4
6 quarters
|
|
7
Praxis Precision Medicines
PRAX
$7.26B
| $11.1M | 5.22% |
33,237
| – | – |
2025 Q1
5 quarters
|
|
8
Cellectis
CLLS
$93.2M
| $9.8M | 4.62% |
3,281,501
| – | – |
2024 Q4
6 quarters
|
|
9
Zai Lab
ZLAB
$2.7B
| $8.56M | 4.02% |
450,646
| – | – |
2024 Q4
6 quarters
|
|
|
10
Structure Therapeutics
GPCR
$1.57B
| $7.51M | 3.53% |
140,000
+12,500
| +10% | +$553K |
2025 Q4
2 quarters
|
|
11
Oruka Therapeutics
ORKA
$4.93B
| $7.14M | 3.35% |
75,000
| – | – |
2024 Q4
6 quarters
|
|
12
Iovance Biotherapeutics
IOVA
$6.44B
| $6.24M | 2.93% |
1,500,000
| – | – |
2024 Q4
6 quarters
|
|
|
13
Spyre Therapeutics
SYRE
$7.92B
| $6.21M | 2.92% |
70,000
-30,000
| -30% | -$2.19M |
2024 Q4
6 quarters
|
|
|
14
Aura Biosciences
AURA
$652M
| $5.43M | 2.55% |
764,243
+166,667
| +28% | +$1.19M |
2024 Q4
6 quarters
|
|
15
Assembly Biosciences
ASMB
$410M
| $4.83M | 2.27% |
175,706
| – | – |
2024 Q4
6 quarters
|
|
16
Bright Minds Biosciences
DRUG
$531M
| $4.74M | 2.22% |
67,500
| – | – |
2026 Q1
1 quarter
|
|
17
Ultragenyx Pharmaceutical
RARE
$1.49B
| $4.51M | 2.12% |
135,000
| – | – |
2024 Q4
6 quarters
|
|
18
Sight Sciences
SGHT
$455M
| $3.66M | 1.72% |
970,000
| – | – |
2024 Q4
6 quarters
|
|
19
Foghorn Therapeutics
FHTX
$111M
| $976K | 0.46% |
200,000
+98,000
| +96% | +$435K |
2026 Q1
1 quarter
|
|
|
20
DELISTED
Apogee Therapeutics
APGE
| – | – |
-7,500
| Closed | -$631K | – |
|
|
21
Replimune Group
REPL
$1.04B
| – | – |
-26,000
| Closed | -$199K | – |
|
|
22
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-7,500
| Closed | -$251K | – |
|
Similar funds
MACM
4FG
KCM
LWP
EWM
HB
AWMM
GL
B Group Inc's Q2 2026 Portfolio in Review
As of Q2 2026, B Group Inc held 22 positions worth $213M, up 58% from $135M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
B Group Inc deployed $17.1M of net new capital in Q2 2026, opening 2 new positions and adding to 5 existing holdings. Its largest new stake was Faeth Therapeutics: 610,169 shares worth $15.3M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Spyre Therapeutics, an estimated $2.19M trimmed.
- B Group Inc's largest Q2 2026 buy was Faeth Therapeutics: 610,169 shares worth $15.3M.
- B Group Inc added most to NRX Pharmaceuticals in Q2 2026, an estimated $3.61M increase.
- B Group Inc's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $2.19M.
- B Group Inc fully exited Apogee Therapeutics in Q2 2026, selling an estimated $631K.
- B Group Inc's ten largest holdings make up 79% of its $213M portfolio in Q2 2026.
- B Group Inc opened 2 new positions and closed 3 in Q2 2026.
- B Group Inc's portfolio value rose 58% quarter-over-quarter to $213M.
Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.